<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/21/head-to-head-contrast-celsion-nasdaqclsn-and-cambrex-nasdaqcbm.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-21T11:35:04+00:00"/>
    <meta property="og:title" content="Head-To-Head Contrast: Celsion (NASDAQ:CLSN) and Cambrex (NASDAQ:CBM)"/>
    <meta property="og:description" content="Celsion (NASDAQ:CLSN) and Cambrex (NYSE:CBM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Profitability This table compares Celsion and Cambrex’s net margins, return on equity and return on assets. Net Margins […]"/>
  </head>
  <body>
    <article>
      <h1>Head-To-Head Contrast: Celsion (NASDAQ:CLSN) and Cambrex (NASDAQ:CBM)</h1>
      <address><time datetime="2019-11-21T11:35:04+00:00">21 Nov 2019, 11:35</time> by <a rel="author" href="https://www.thecerbatgem.com/author/doug" target="_blank">Doug Wharley</a></address>
      <p>Celsion (<a href="https://www.marketbeat.com/stocks/NASDAQ/CLSN/">NASDAQ:CLSN</a>) and Cambrex (<a href="https://www.marketbeat.com/stocks/NYSE/CBM/">NYSE:CBM</a>) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.</p>
      <p>
        <b>Profitability</b>
      </p>
      <p>This table compares Celsion and Cambrex’s net margins, return on equity and return on assets.</p>
      <table bordered="">
        <tr>
          <td/>
          <td>
            <b>Net Margins</b>
          </td>
          <td>
            <b>Return on Equity</b>
          </td>
          <td>
            <b>Return on Assets</b>
          </td>
        </tr>
        <tr>
          <td>
            <b>Celsion</b>
          </td>
          <td>-1,653.20%</td>
          <td>-57.46%</td>
          <td>-24.93%</td>
        </tr>
        <tr>
          <td>
            <b>Cambrex</b>
          </td>
          <td>5.96%</td>
          <td>5.38%</td>
          <td>2.50%</td>
        </tr>
      </table>
      <p>
        <b>Institutional &amp; Insider Ownership</b>
      </p>
      <p>5.3% of Celsion shares are owned by institutional investors. Comparatively, 93.4% of Cambrex shares are owned by institutional investors. 9.3% of Celsion shares are owned by company insiders. Comparatively, 1.4% of Cambrex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.</p>
      <p>
        <b>Valuation and Earnings</b>
      </p>
      <p>This table compares Celsion and Cambrex’s top-line revenue, earnings per share (EPS) and valuation.</p>
      <table bordered="">
        <tr>
          <td/>
          <td>
            <b>Gross Revenue</b>
          </td>
          <td>
            <b>Price/Sales Ratio</b>
          </td>
          <td>
            <b>Net Income</b>
          </td>
          <td>
            <b>Earnings Per Share</b>
          </td>
          <td>
            <b>Price/Earnings Ratio</b>
          </td>
        </tr>
        <tr>
          <td>
            <b>Celsion</b>
          </td>
          <td>$500,000.00</td>
          <td>61.90</td>
          <td>-$11.88 million</td>
          <td>($0.68)</td>
          <td>-2.00</td>
        </tr>
        <tr>
          <td>
            <b>Cambrex</b>
          </td>
          <td>$532.09 million</td>
          <td>3.79</td>
          <td>$92.41 million</td>
          <td>$2.77</td>
          <td>21.61</td>
        </tr>
      </table>
      <p>Cambrex has higher revenue and earnings than Celsion. Celsion is trading at a lower price-to-earnings ratio than Cambrex, indicating that it is currently the more affordable of the two stocks.</p>
      <p>
        <b>Risk and Volatility</b>
      </p>
      <p>Celsion has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&amp;P 500. Comparatively, Cambrex has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&amp;P 500.</p>
      <p>
        <b>Analyst Recommendations</b>
      </p>
      <p>This is a summary of current ratings and price targets for Celsion and Cambrex, as provided by MarketBeat.</p>
      <table bordered="">
        <tr>
          <td/>
          <td>
            <b>Sell Ratings</b>
          </td>
          <td>
            <b>Hold Ratings</b>
          </td>
          <td>
            <b>Buy Ratings</b>
          </td>
          <td>
            <b>Strong Buy Ratings</b>
          </td>
          <td>
            <b>Rating Score</b>
          </td>
        </tr>
        <tr>
          <td>
            <b>Celsion</b>
          </td>
          <td>0</td>
          <td>0</td>
          <td>2</td>
          <td>0</td>
          <td>3.00</td>
        </tr>
        <tr>
          <td>
            <b>Cambrex</b>
          </td>
          <td>0</td>
          <td>4</td>
          <td>1</td>
          <td>0</td>
          <td>2.20</td>
        </tr>
      </table>
      <p>Cambrex has a consensus price target of $52.40, indicating a potential downside of 12.48%. Given Cambrex’s higher possible upside, analysts clearly believe Cambrex is more favorable than Celsion.</p>
      <p>
        <b>Summary</b>
      </p>
      <p>Cambrex beats Celsion on 10 of the 14 factors compared between the two stocks.</p>
      <p>
        <b>Celsion Company Profile</b>
      </p>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/celsion-co-logo.jpg"/>
      </figure>
      <p>Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.</p>
      <p>
        <b>Cambrex Company Profile</b>
      </p>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/cambrex-co-logo.png"/>
      </figure>
      <p>Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.</p>
    </article>
  </body>
</html>